주요우울장애 환자 치료에서 보조요법으로서의 루마테페론 연구
주요 우울 장애 환자 치료에서 보조 요법으로서 Lumateperone의 효능과 안전성을 평가하기 위한 무작위, 이중 맹검, 위약 대조 다기관 연구
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The study will be conducted in three periods:
- Screening Period (up to 2 weeks) during which patient eligibility will be assessed.
- Double-blind Treatment Period (6 weeks) in which all patients will be randomized to receive placebo or lumateperone 42 mg/day in 1:1 ratio.
- Safety Follow-up Period (1 week) in which all patients will return to the clinic for a safety follow-up visit approximately one week after the last dose of study treatment.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Kaunas, 리투아니아, LT-44279
- 완전한
- Romuvos Klinika, JSC
-
Ziegzdriai, 리투아니아, 53136
- 완전한
- Kaunas Hospital of Lithuanian University of Health Sciences Psychiatric Clinic Mariu division
-
-
-
-
Alabama
-
Huntsville, Alabama, 미국, 35801
- 모병
- University of Alabama at Birmingham
-
-
California
-
Pico Rivera, California, 미국, 90660
- 모병
- CNRI-Los Angeles, LLC
-
-
Connecticut
-
Farmington, Connecticut, 미국, 06030
- 모병
- University of Connecticut Health Center
-
-
Florida
-
Clermont, Florida, 미국, 34711
- 종료됨
- Vertex Clinical Research
-
Hialeah, Florida, 미국, 33012
- 정지된
- New Life Medical Research Center, Inc.
-
Miami, Florida, 미국, 33122
- 모병
- Premier Clinical Research Institute
-
Miami, Florida, 미국, 33137
- 모병
- Miami Jewish Health System
-
Tampa, Florida, 미국, 33629
- 모병
- Interventional Psychiatry of Tampa Bay
-
-
Georgia
-
Atlanta, Georgia, 미국, 30329
- 모병
- The Emory Clinic
-
Decatur, Georgia, 미국, 30030
- 모병
- CenExeli Research LLC
-
-
Kansas
-
Kansas City, Kansas, 미국, 66160
- 종료됨
- University of Kansas Medical Center Research Institute
-
Overland Park, Kansas, 미국, 66210
- 모병
- Collective Medical Research
-
-
Massachusetts
-
Methuen, Massachusetts, 미국, 01844
- 종료됨
- ActivMed Practices and Research
-
-
Missouri
-
O'Fallon, Missouri, 미국, 63368
- 모병
- Psychiatric Care and Research Center (PCRC)
-
-
New Jersey
-
Toms River, New Jersey, 미국, 08755
- 모병
- Bio Behavioral Health
-
-
New York
-
Brooklyn, New York, 미국, 11235
- 모병
- SPRI Clinical Trials, LLC
-
New York, New York, 미국, 10036
- 모병
- Manhattan Behavioral Medicine
-
-
Ohio
-
Avon Lake, Ohio, 미국, 44012
- 모병
- Quest Therapeutics of Avon Lake
-
Cincinnati, Ohio, 미국, 45219
- 모병
- University of Cincinnati Medical Center
-
Columbus, Ohio, 미국, 43210
- 모병
- The Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- University of Pennsylvania - Perelman School of Medicine
-
-
Texas
-
Houston, Texas, 미국, 77081
- 모병
- DM Clinical Research
-
Mansfield, Texas, 미국, 76063
- 완전한
- Hawkins Psychiatry, PC
-
Richardson, Texas, 미국, 75080
- 모병
- Pillar Clinical Research, LLC
-
-
Washington
-
Bellevue, Washington, 미국, 98007
- 모병
- Northwest Clinical Research Center
-
-
-
-
-
Cherven Bryag, 불가리아, 5980
- 모병
- Ambulatory for Individual Practice for Specialized Medical Care in Psychiatry Dr. Ivo Natsov ET
-
Kardzhali, 불가리아, 6600
- 모병
- Medical Center Lifemed
-
Pleven, 불가리아, 5800
- 모병
- Medical Center Medconsult-Pleven
-
Plovdiv, 불가리아, 4004
- 모병
- Medical Center Mentalcare OOD
-
Sofia, 불가리아, 1680
- 모병
- Medical Center Intermedica, OOD
-
Sofia, 불가리아, 1510
- 모병
- Medical Center Hera EOOD
-
Sofia, 불가리아, 1202
- 모병
- MHC - Sofia, EOOD
-
Sofia, 불가리아, 1431
- 종료됨
- University Multiprofile Hospital for Active Treatment - UMHAT Alexandrovska EAD
-
Stara Zagora, 불가리아, 6003
- 완전한
- UMHAT Prof. Dr. St. Kirkovich AD
-
Varna, 불가리아, 9020
- 모병
- Diagnostic Consulting Center Mladost - M Varna
-
-
-
-
-
Belgrade, 세르비아, 11000
- 모병
- University Clinical Center of Serbia
-
Belgrade, 세르비아, 11000
- 모병
- Institute of Mental Health Serbia
-
Belgrade, 세르비아, 11000
- 모병
- Clinical Center Dr Dragisa Misovic Dedinje
-
Kovin, 세르비아, 26220
- 모병
- Special Hospital for Psychiatric Diseases Kovin
-
Kragujevac, 세르비아, 34000
- 모병
- University Clinical Center Kragujevac
-
Kragujevac, 세르비아, 34000
- 모병
- University Clinical Center Kragujevac 1
-
Niš, 세르비아, 18000
- 모병
- University Clinical Center NIS 1
-
Niš, 세르비아, 18000
- 모병
- University Clinical Center NIS
-
Novi Kneževac, 세르비아, 23330
- 모병
- Special Hospital for Psychiatric Diseases Sveti Vracevi
-
-
-
-
-
Barcelona, 스페인, 08036
- 모병
- Hosp. Clinic de Barcelona
-
Barcelona, 스페인, 08035
- 모병
- Hosp Univ Vall D Hebron
-
Madrid, 스페인, 28034
- 완전한
- Hosp. Univ. Ramon Y Cajal
-
Sabadell, 스페인, 08208
- 모병
- Hosp.Univ.Parc Tauli
-
Zamora, 스페인, 49021
- 모병
- Hosp. Prov. de Zamora
-
-
-
-
-
Ahmedabad, 인도, 380008
- 정지된
- Ratandeep Surgical Hospital And Endoscopy Clinic
-
Ahmedabad, 인도, 380009
- 정지된
- Sushrusha Navneet Memorial Hospital
-
Ajmer, 인도, 305001
- 정지된
- J L N Medical College and Attached Hospitals
-
Bikaner, 인도, 334001
- 모병
- S P Medical College And Associated Group of Hospitals
-
Bārāmati, 인도, 413102
- 모병
- Baramati Hospital
-
Chandigarh, 인도, 160012
- 모병
- Post Graduate Institute of Medical Education And Research PGIMER
-
Guwahati, 인도, 781032
- 완전한
- Gauhati Medical College and Hospital
-
Kolhāpur, 인도, 416001
- 모병
- Swastik Hospital
-
Nagpur, 인도, 440001
- 모병
- KIMS-Kingsway Hospitals
-
Palsāna, 인도, 394315
- 모병
- Divyam Hospital
-
Pune, 인도, 411011
- 모병
- Shree Samarth Hospital
-
Rajkot, 인도, 360001
- 완전한
- Nagecha Hospital
-
Wardha, 인도, 442004
- 정지된
- Acharya vinoba bhave rural hospital
-
-
-
-
-
Douai, 프랑스, 59500
- 모병
- Cabinet Medical des Drs Prizac-Desbonnet Scottez
-
Nantes, 프랑스, 44093
- 모병
- CHU de Nantes hotel Dieu
-
Nîmes, 프랑스, 30029
- 모병
- Hopital Caremeau
-
Paris, 프랑스, 75012
- 모병
- Groupe Hospitalier Pitie-Salpetriere
-
Poitiers, 프랑스, 86021
- 모병
- CH Henri Laborit
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Male or female patients between the ages of 18 and 65 years, inclusive;
-
Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:
- The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening;
- Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline;
- Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline;
- Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline;
- Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
-
Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:
- citalopram/escitalopram
- fluoxetine
- paroxetine
- sertraline
- duloxetine
- levomilnacipran/milnacipran (if locally approved for MDD)
- venlafaxine/desvenlafaxine
- bupropion
- vilazodone
- vortioxetine
Exclusion Criteria:
-
Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder;
- Bipolar Disorder;
-
Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment;
- Eating disorder;
- Substance use disorders (excluding nicotine);
- Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status;
- Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
-
The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline;
-
The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline;
-
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit;
- At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening;
- At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or
- The patient is considered to be in imminent danger to him/herself or others.
-
The patient has a first MDE at age 60 years or older.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: 위약
|
Matching capsules administered orally, once daily |
|
실험적: 루마테페론 42mg
|
Lumateperone 42 mg capsules administered orally, once daily |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Montgomery-Asberg Depression Rating Scale
기간: Day 43
|
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms. |
Day 43
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical Global Impression Scale-Severity
기간: Day 43
|
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). |
Day 43
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Intra-Cellular Therapies, Inc. Clinical Trial, Intra-Cellular Therapies, Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- ITI-007-505
- ITI-007-505 (기타 식별자: Janssen Research & Development, LLC)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .